Payment overview · 2025
General Payments
$890.35
51 reported records · 13 companies
Healthcare provider profile · identity verified
James E Malone, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BRIDGEPORT, WV · NPI 1134225832
Verified facts
What the public records show
CMS Open Payments records show James E Malone, D.O. received $890.35 in general payments during 2025 across 51 reported records.
Novo Nordisk Inc accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 625 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $218.11 | 24.5% | 12 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $152.72 | 17.1% | 10 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $151.31 | 17.0% | 10 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $75.47 | 8.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.49 | 6.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.73 | 5.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.80 | 4.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.67 | 4.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.90 | 3.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.68 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.44 | 2.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.28 | 2.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.75 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $890.35 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $151.31 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $116.78 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $99.76 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $91.56 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $77.64 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $75.47 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $56.49 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $52.96 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.73 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $40.80 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.80 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.67 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $26.90 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 625 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
85 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
83 | 76 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
625 | 77 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1547 | 210 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1446 | 195 |
| Amlodipine Besylate | Amlodipine Besylate | 1425 | 156 |
| Sertraline Hcl | Sertraline Hcl | 1232 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1188 | 183 |
| Famotidine | Famotidine | 1024 | 121 |
| Metoprolol Tartrate | Metoprolol Tartrate | 831 | 100 |
| Clopidogrel | Clopidogrel Bisulfate | 813 | 85 |
| Furosemide | Furosemide | 802 | 123 |
| Tamsulosin Hcl | Tamsulosin Hcl | 782 | 89 |
| Lisinopril | Lisinopril | 726 | 106 |
| Gabapentin | Gabapentin | 719 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 717 | 167 |
| Trazodone Hcl | Trazodone Hcl | 672 | 72 |
| Citalopram Hbr | Citalopram Hydrobromide | 658 | 75 |
| Tramadol Hcl | Tramadol Hcl | 653 | 64 |
| Omeprazole | Omeprazole | 626 | 121 |
| Eliquis | Apixaban | 625 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 583 | 92 |
| Montelukast Sodium | Montelukast Sodium | 578 | 90 |
| Potassium Chloride | Potassium Chloride | 575 | 89 |
| Jardiance | Empagliflozin | 548 | 69 |
| Carvedilol | Carvedilol | 526 | 51 |
| Donepezil Hcl | Donepezil Hcl | 480 | 47 |
| Levetiracetam | Levetiracetam | 477 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 454 | 69 |
| Mirtazapine | Mirtazapine | 454 | 63 |
| Losartan Potassium | Losartan Potassium | 440 | 76 |
| Divalproex Sodium | Divalproex Sodium | 387 | 36 |
| Carbamazepine | Carbamazepine | 364 | 31 |
| Simvastatin | Simvastatin | 362 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 341 | 55 |
| Lorazepam | Lorazepam | 316 | 38 |
| Xarelto | Rivaroxaban | 310 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 309 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 308 | 61 |
| Metformin Hcl | Metformin Hcl | 279 | 71 |
| Memantine Hcl | Memantine Hcl | 267 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 230 | 28 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 217 | 18 |
| Metformin Hcl Er | Metformin Hcl | 211 | 45 |
| Valsartan | Valsartan | 207 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 200 | 18 |
| Finasteride | Finasteride | 182 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 176 | 39 |
| Propranolol Hcl | Propranolol Hcl | 174 | 13 |
| Ezetimibe | Ezetimibe | 172 | 42 |
| Prednisone | Prednisone | 171 | 81 |
| Quetiapine Fumarate | Quetiapine Fumarate | 167 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 162 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 153 | 82 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 151 | 22 |
| Chlorthalidone | Chlorthalidone | 141 | 24 |
| Ozempic | Semaglutide | 139 | 18 |
| Enulose | Lactulose | 138 | 20 |
| Meloxicam | Meloxicam | 137 | 38 |
| Spironolactone | Spironolactone | 136 | 23 |
| Clonazepam | Clonazepam | 133 | 15 |
| Lamotrigine | Lamotrigine | 128 | suppressed |
| Torsemide | Torsemide | 126 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 125 | 66 |
| Alprazolam | Alprazolam | 120 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 120 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 114 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 57 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 113 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 113 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 27 |
| Warfarin Sodium | Warfarin Sodium | 107 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 26 |
| Olanzapine | Olanzapine | 100 | 11 |
| Sucralfate | Sucralfate | 97 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 96 | 11 |
| Memantine Hcl Er | Memantine Hcl | 93 | suppressed |
| Celecoxib | Celecoxib | 92 | 16 |
| Allopurinol | Allopurinol | 91 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 87 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 47 |
| Breo Ellipta | Fluticasone/Vilanterol | 86 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 33 |
| Myrbetriq | Mirabegron | 85 | 14 |
| Phenytoin | Phenytoin | 85 | suppressed |
| Primidone | Primidone | 85 | suppressed |
| Entresto | Sacubitril/Valsartan | 84 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 83 | 76 |
| Doxepin Hcl | Doxepin Hcl | 81 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 81 | 16 |
| Atenolol | Atenolol | 80 | 13 |
| Methylprednisolone | Methylprednisolone | 80 | 66 |
| Oxybutynin Chloride | Oxybutynin Chloride | 79 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 77 | 33 |
| Azelastine Hcl | Azelastine Hcl | 76 | 34 |
| Carbamazepine Er | Carbamazepine | 72 | suppressed |
| Xifaxan | Rifaximin | 70 | suppressed |
| Nifedipine Er | Nifedipine | 68 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 20 |
| Buspirone Hcl | Buspirone Hcl | 65 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 62 | 16 |
| Baclofen | Baclofen | 61 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 61 | 36 |
| Cephalexin | Cephalexin | 60 | 35 |
| Ziprasidone Hcl | Ziprasidone Hcl | 60 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 59 | 33 |
| Linzess | Linaclotide | 59 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 58 | suppressed |
| Synthroid | Levothyroxine Sodium | 57 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 43 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | suppressed |
| Januvia | Sitagliptin Phosphate | 54 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 18 |
| Budesonide | Budesonide | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 51 | 11 |
| Farxiga | Dapagliflozin Propanediol | 51 | 14 |
| Tetrabenazine | Tetrabenazine | 51 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 50 | 14 |
| Latanoprost | Latanoprost | 48 | 12 |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 48 | 40 |
| Glimepiride | Glimepiride | 47 | 14 |
| Anastrozole | Anastrozole | 46 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 46 | suppressed |
| Lacosamide | Lacosamide | 46 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | 13 |
| Methocarbamol | Methocarbamol | 43 | 13 |
| Meclizine Hcl | Meclizine Hcl | 42 | 17 |
| Colchicine | Colchicine | 41 | 14 |
| Fluconazole | Fluconazole | 41 | 27 |
| Metronidazole | Metronidazole | 41 | 11 |
| Valacyclovir | Valacyclovir Hcl | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 38 | suppressed |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 30 |
| Topiramate | Topiramate | 37 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Acetazolamide | Acetazolamide | 34 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Cefdinir | Cefdinir | 33 | 25 |
| Clonidine | Clonidine | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 14 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 31 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | 20 |
| Albuterol Sulfate | Albuterol Sulfate | 29 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 27 | suppressed |
| Daptomycin | Daptomycin | 26 | suppressed |
| Nystatin | Nystatin | 26 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Cyclosporine | Cyclosporine | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 15 |
| Aptiom | Eslicarbazepine Acetate | 24 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Dalfampridine Er | Dalfampridine | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 19 |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Acetic Acid | Acetic Acid | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Pentoxifylline | Pentoxifylline | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 16 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 14 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Ertapenem | Ertapenem Sodium | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Flurbiprofen | Flurbiprofen | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Sodium Fluoride 5000 Plus | Fluoride (Sodium) | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 12 | suppressed |
| Linezolid | Linezolid | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Methylphenidate Er (La) | Methylphenidate Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $890.35 · 51 records | Novo Nordisk Inc | CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, Kerendia, NEXLETOL, NURTEC ODT, Ohtuvayre, Ozempic, PROLIA, REXULTI, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, VOQUEZNA, Veozah, Wegovy, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error